Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - THRESHOLD PHARMACEUTICALS INCv238414_ex99-1.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2011
 
THRESHOLD PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-32979
94-3409596
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
  Identification No.)
 
170 Harbor Way, Suite 300
South San Francisco, California 94080
(Address of principal executive offices)(Zip Code)
 
(650) 474-8200
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 

 
 
Item 8.01   
Other Events.

On October 28, 2011, Threshold Pharmaceuticals, Inc. issued a press release announcing clinical trial results related to Threshold’s Phase 3 clinical stage hypoxia-activated prodrug, TH-302.  The press release is attached as Exhibit 99.1 to this Form 8-K.
.
Item 9.01    
Financial Statements and Exhibits.
 
(d) Exhibits

Exhibit 99.1         Press release dated October 28, 2011.
 
 
 

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
THRESHOLD PHARMACEUTICALS, INC.
 
       
 
By:
/s/ Joel A. Fernandes         
    Joel A. Fernandes  
   
Vice President, Finance and Controller
 
       
 
Date:  October 28, 2011
 
 
 

 

Exhibit Index
 
Exhibit No.
Description
   
Exhibit 99.1
Press release dated October 28, 2011.